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ABSTRACT
SHIWANI THAPA: Potential interactions between GPER1 and HIV Tat-mediated neurotoxicity
(Under the direction of Dr. Jason Paris)
Great advances have been made in the treatment of HIV, however, new infections remain
consistent each year with no effective cure. The early entry of HIV virus into the central nervous
system is thought to contribute to the development of HIV-associated neurocognitive disorders.
One of the mechanisms of neurological impairment may involve actions of the neurotoxic HIV
viral protein, trans-activator of transcription (Tat). Tat can be secreted from infected cells and
acts as an excitotoxin, increasing the intracellular flux of Ca2+ , promoting mitochondrial
dysfunction, and neural cell damage/death. Previous experiments have shown that steroid
hormones such as estrogen can exert protective effects against Tat-mediated neurotoxicity; but,
the site(s) of this protection action are unclear. The primary purpose of this thesis was to begin to
assess the role of the non-traditional estrogen receptor, G-protein coupled receptor 1 (GPER1), in
Tat-mediated neurotoxicity. The capacity of a GPER1 agonist and antagonist were assessed for
their influence on Tat-induced production of reactive oxygen species (ROS) and subsequent cell
death using SH-SY5Y human neuroblastoma cells. The results revealed that GPER1 agonism
attenuated Tat induced ROS production and prevented Tat-mediated cell death. Conversely,
antagonizing GPER1 modestly reduced ROS production; albeit, did not completely attenuate
Tat-mediated increases, and exert no effects on cell death.
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Further investigation of non-traditional sites of endocrine action may reveal novel therapeutic
targets for the treatment of neurological diseases, within and beyond the field of neuroHIV.
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1. INTRODUCTION:
a. Prevalence of HIV worldwide and in the U.S.:
The human immunodeficiency virus (HIV) remains an ongoing concern worldwide and in the
United States with no effective cure. Since the start of the HIV epidemic, 75.7 million people
have been infected and approximately 32.7 million people have died from acquired
immunodeficiency syndrome (AIDS) or related illnesses (UNAIDS, 2020). Worldwide, there are
currently about 38 million people globally living with HIV in 2019 (36.2 million adults and 1.8
million children; UNAIDS, 2020). Although progress has been achieved in preventing and
treating HIV, there were an estimated 1.2 million people living with HIV in the United States at
the end of 2018 (CDC, 2021). HIV can be transmitted via contact with bodily fluids (blood,
semen, rectal fluids, vaginal fluids and breast milk) from an infected person. Transmission
occurs when these fluids come in contact with a mucous membrane or a damaged tissue or are
directly injected (from needle or syringe; CDC, 2020). The pathogenesis and transmission
dynamics concerning HIV have evolved in the post-combined antiretroviral therapeutic (cART)
era.Treatment options are now available, however vaccine and cure strategies remain to be
achieved (Simon, et al., 2006). The development of cART has greatly reduced medical morbidity
and mortality, but still has not decreased the prevalence of HIV-associated neurocognitive
disorders (HAND; Heaton, et al., 2011) wherein infection manifests as neurological disturbances
in approximately 50% of HIV-infected patients (Saylor, et al., 2016).
b. HIV-associated neurocognitive disorders (HAND)
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HAND is characterized by impaired short term memory along with neurological
disorders ranging from mild difficulty with concentration, impaired decision-making, and lack of
coordination, to progressive dementia (Ghosh, et al., 2017). Notably, in the post-cART era, the
most severe form of cognitive impairment (HIV-associated dementia) has been reduced (~2%).
But the prevalence of additional cognitive impairment remains. In the modern day, HAND is
characterized by asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder
(MND), and to a lesser extent HIV-associated dementia (Ghosh, et al., 2017). The
neuropathogenesis of HAND is generally considered to be initiated and driven by HIV invasion
and replication within the brain parenchyma. This occurs via productive infection of brain
perivascular macrophages and endogenous microglia, and perhaps to some degree by restricted
infection of astrocytes. This invasion of the central nervous system (CNS) is believed to occur
early in HIV infection (Heaton, et al., 2011). The CNS can subsequently serve as a reservoir for
ongoing HIV replication, thereby limiting the opportunity for treatment (Heaton, et al., 2011).
Importantly, cART is poorly retained within the CNS and cannot target latent HIV reservoirs
(Fields, et al., 2019). As such, cART cannot presently eradicate HIV from the CNS compartment.
HAND combined with a unique spectrum of opportunistic infections and malignancy, comprise
neuroHIV (Clifford, et al., 2013).
c. NeuroHIV
Within hours of viral acquisition (An, et al., 1999), HIV enters the CNS. Although the
entry mechanism remains debated, there is strong support for what has become known as the
“Trojan horse” theory. This theory postulates that soon after seroconversion, infected monocytes
can traverse the brain microvascular endothelium. Monocyte-derived cells become easily
infected. Both the immature monocytes or mature macrophages do not divide. In contrast,
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because of their highly proliferative nature, infected CD4+ T-lymphocytes produce large levels
of virus in the periphery. Thus monocytes, macrophages, and/or lymphocytes may carry the virus
into the brain during disease. Free progeny virus may also cross the blood-brain barrier (BBB)
before infecting monocyte lineage cells in the perivascular space (Zink et al., 1999). The infected
macrophages can cause neuronal damage and destruction through multiple mechanisms (Zink et
al., 1999).
Neurological disorders (NDs) in persons infected with HIV are largely caused by three
main mechanisms, direct effects of HIV infection and toxic protein production, indirect
neuroinflammation, and opportunistic processes as a result of immune challenge (Lucas, et al.,
2015). Microglial cells, the CNS resident macrophages, are one of the major cellular reservoirs
of latent HIV. This reservoir contributes to cognitive deterioration in the different forms of
HAND that involve an increase in proinflammatory cytokines and increased neurotoxins that
affect both astrocytes and neurons, promoting apoptosis (Adle-Biassette, et al., 1995). These
cells are believed to be involved in the emergence of drug resistance and potentially re-seeding
peripheral tissues following BBB disruption (Wallet, et al., 2019). The BBB is a selective barrier
composed of microvascular endothelial cells lining the brain microvessels. It has an active
interface between the circulation and the CNS, restricts free movement of substances between
blood and CNS, and is critical in maintaining CNS homeostasis (Wilhelm, et al., 2011).
HIV-derived cellular and viral toxins are known to alter the integrity of the BBB. Exposure to
HIV alters tight junction expression (Dallasta et al. 1999; Boven et al. 2000; Persidsky et al.
2006; Chaudhuri et al. 2008b, a; Eugenin et al. 2011) and also increases transmigration of cells
across the barrier (McRae, 2016). The mechanisms of HIV’s capacity for neurological damage
are largely thought to be driven by production of cytotoxic and/or pro-inflammatory HIV
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proteins. Some proteins exert direct effects to promote neurotoxicity while others activate central
reservoirs that mediate neuroinflammation.
d. HIV neurotoxic proteins: gp120, VPR, Tat
Several neurotoxins are produced by HIV that can promote neurotoxicity. The gp160
glycoprotein complex comprises the outer coat of the HIV virion. It presents itself as viral
membrane spikes consisting of gp120 linked together and anchored to the membrane by gp41
protein (Yoon et al., 2010). The HIV envelope protein, gp120, initiates virus entry into T cells or
macrophages through attachment to the CD4 molecule and subsequent binding to a chemokine
coreceptor, CXCR4 or CCR5, depending on viral tropism (Bluel CC et al., 1996; Schmitz J E et
al., 1999). Direct interaction of gp120 with either CCR5 and CXCR4, as well as
N-methyl-D-aspartate (NMDA) receptors on neuronal surfaces promotes intracellular calcium
influx, the generation of reactive oxygen species (ROS), and the activation of signaling pathways
that lead to cellular apoptosis (Smith, et al., 2018). HIV viral protein R (Vpr) plays a unique role
in neuropathogenesis with its ability to induce G2/M arrest along with its capacity to increase
viral gene transcription (James, et al., 2016). Vpr can be released from HIV-infected cells and
taken up by uninfected neuronal cells. Once Vpr enters the cells, it can act to increase
intracellular calcium, driving mitochondrial dysfunction and ROS production. Although Vpr
increases the permeability of the cytosolic membrane, it was found that Vpr inhibits calcium
release from the cells by affecting endogenous levels of the plasma membrane Ca2+ ATPase
(PMCA). Thus, it is likely that Vpr induces an array of biological events downstream of its
capacity to dysregulate neuronal calcium homeostasis (Rom, et al., 2009). Other effects of Vpr
include changes in cell cycle progression, dysregulation of cellular metabolism and signaling,
and loss of cell viability (James, et al., 2016). However, one of the most well-studied neurotoxic
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HIV proteins is the transactivator of transcription (Tat), which was the subject of the present
thesis.
e. Tat
Tat is a viral HIV protein which is secreted from infected monocyte-derived cells
(predominantly microglia and perivascular macrophages) within the CNS (Re M C et al., 1995;
Hudson et al., 2000). It is present in the brain of HIV-infected individuals with and without
cART treatment (Hudson et al., 2000). Tat is an essential viral protein for HIV replication and is
critical for the stimulation of latently infected cells (Frankel et al., 1988). It promotes indirect
neurotoxicity via the activation of glial cells, such as the microglia or astrocytes, that produce
proinflammatory cytokines (Ensoli et al., 1993). It plays a critical role in viral rebound caused
by interruptions in cART (Jin et al., 2020). Tat also exerts direct neurotoxic effects on neurons,
independently or in concert with other viral proteins and inflammatory toxins to promote
excitotoxic neuronal injury and/or death (Mattson et al., 2005). Tat activates NMDA receptors
(Dreyer et al., 1990; Eugenin et al., 2007; Li et al., 2008), interrupts mitochondrial function
(Brooke et al., 1998; Perry et al., 2005) and ATP production (Brooke et al., 1998; Norman et al.,
2007; Turchan-Cholewo et al., 2006), and disrupts ion homeostasis (Ca2+, Na+, and perhaps K+;
Fitting et al., 2014; Greenwood and Connolly, 2007; Lee et al., 2003; Perry et al., 2005) resulting
in synapto-dendritic injury (Greenwood et al., 2007; Park et al., 1996). As Tat can be released by
infected monocytes and macrophages, it can accumulate at the BBB (Rayne, et al., 2010) and
induce changes either via receptor-mediated pathways or through a direct uptake of the protein
via active endocytosis (Rayne et al., 2010; De Marco et al., 2010). Tat also degrades tight
junctions of brain endothelial cells via inhibiting occludin and promoting matrix
metalloproteinase 9 cleavage (Xu et al., 2012). Shortly after exposure to Tat, rapid release of
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ROS suggests impaired mitochondria membrane potential leading to alterations in mitochondrial
size and subcellular localization in a calcineurin-dependent manner. Hence, Tat impairs
mitochondrial dynamics in neurons, contributing to cell death (Rozzi et al., 2018).
f. Gender Differences in HIV acquisition:
Tat-mediated insults on the CNS are ameliorated by exogenous administration of steroid
hormones (Kendall et al., 2005). In a study, long-term HIV Tat expression in the brain led to
impaired short- and long-term memory but with more impairment in male mice (Marks et al.,
2016; Qrareya et al., 2020). Moreover, aging-associated menopause, accompanied by estrogen
decline may be related to the worse memory in females (Diaz and Roberta, 2012), which may
further exacerbate the impact of Tat on female mice (Zhao et al., 2020; Qraryea et al., 2020). In a
transgenic mouse model, HIV Tat 1-86 is conditionally expressed in a CNS-targeted manner to
demonstrate Tat-driven microgliosis within the striatum of male and female mice (Hahn et al.,
2015). In a similar transgenic model, conditional Tat exposure was observed to increase
microglial activation throughout limbic and extra-limbic brain regions of male mice (Paris et al.,
2015). However, in an examination of sex differences, reactive nitrogen species were
co-localized with microglia to a lesser extent in females, compared to males (Hahn et al., 2015).
This coincided with reduced neuronal cell death, astrogliosis, and reduced motor/anxiety-like
pathology among females exposed to central HIV Tat (Hahn et al., 2015). As such, gender may
confer protection to some of Tat’s neuroinflammatory and neurotoxic effects, but the
mechanisms are not known. Classic steroid hormones and their neuroprotective metabolites may
improve outcomes following exposure to HIV Tat (Paris et al., 2016). In support, classic estrogen
actions reduce neurotoxicity in human cell cultures (Adams et al., 2010). In people, estrogen
applied directly to the genital tract of post-menopausal women provides both enhanced barrier
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function and reduced proinflammatory cytokine production in local epithelial cells when
challenged with HIV (Dizzell et al., 2019). More recent studies reveal that estrogens may exert
rapid signaling via actions at G protein-coupled receptors (Rodenas et al., 2017).
g. GPER1:
Traditionally, estrogens were thought to exclusively act via classical nuclear estrogen
receptors (ERs), namely ERα. A second isoform of the classic nuclear receptor was later
identified as ERβ (MacGregor et al., 1998). However, it has since been observed that some
estrogens induce biological effects in only minutes after their application. This rapid effect of
estrogens is thought to occur too quickly for canonical nuclear gene transcription and is rather
thought to be mediated by novel receptors that exert transcriptional regulation via rapid signal
transduction (i.e. “non-genomic”). One such estrogen-sensitive protein that has been identified is
the G protein-coupled estrogen receptor 1 (GPER1; Rodenas et al., 2017). GPER1 (formerly
known as GPR30) is thought to be localized at the cell membrane in its inactive state and is
shown to activate kinase cascades and calcium (Ca2+) flux within cells rapidly following
activation (Maria and Nandini, 2018). This notion is conceptually consistent with predictions of
a membrane-ER (mER) that can mediate non-genomic signaling by estrogens. GPER1
expression is widespread in the central nervous system (CNS) and contributes to spatial memory,
anxiety, social memory, and lordosis behavior in mice (Hadjimarkou, Maria M, and Nandini
Vasudevan, 2017). These data indicate that estrogens regulate normal function in the nervous,
immune, skeletal, and cardiovascular systems, adipocytes, liver, pancreas, and kidney by
activating GPER1 (Prossnitz, Eric R, and Helen J Hathaway, 2015). In the brain, GPER1
signaling, in response to estrogen, facilitates neuroprotection, social behaviors and cognition
(Vajaria, et al., 2018). The GPER1 is Gs-coupled and inhibits Erk-1/-2 activity (Filardo, et al.,
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2002). GPER1 also activates cell-signaling cascades driven by phosphatidylinositol-3-OH kinase
(PI3K; Revankar et al., 2005; Petrie et al., 2013), protein kinase C (PKC; Goswami et al., 2011),
calcium mobilization (Revankar et al., 2005; Tica et al., 2011), and activation of other ion
channels (Fraser et al., 2010; Goswami et al., 2011). Moreover, GPER1 is thought to
dynamically modulate the PMCA which rectifies intracellular Ca2+ content (Tran, et al., 2015).
GPER1 may thus contribute to estradiol’s protective actions over HIV Tat, perhaps via its
capacity to offset Tat’s Ca2+-mobilizing capacity thereby reducing mitochondrial dysfunction,
ROS generation, and ultimately neuronal damage/death.
h. Hypothesis:
We anticipated that activation of GPER1 contributes to estradiol’s protective effects on
Tat-induced neurotoxicity. To test this, we conducted in vitro experiments using differentiated
SH-SY5Y human neuroblastoma cells that were exposed (or not) to Tat protein and assessed for
generation of ROS and subsequent cell death. We hypothesized that a GPER1 agonist, G1, would
express potentially-protective effects over Tat-mediated cytotoxicity whereas the GPER1
antagonist, G36, would not.
2. MATERIALS and METHODS:
2.1 Cell Culture
Human SH-SY5Y neuroblastoma cells were obtained from ATCC (#CRL2266;
Manassas, VA). These cells were seeded onto 96- or 24-well plates at a density of 0.5×104/well
or 4 × 104/well, respectively, and maintained in growth medium: 89.5% DMEM/F12 (Life
Technologies, Carlsbad, CA), 10% heat-inactivated fetal bovine serum (FBS; Thermo Scientific
Hyclone, Logan, UT), and 0.5% antibiotic/antimycotic mixture (Life Technologies). Prior to
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differentiation, these cells were incubated (37°C, 5% CO2) and media was replaced every 2-3
days.
2.2 Differentiation:
The day after seeding, the growth medium was fully exchanged for differentiation
medium #1. Differentiation medium #1 contained retinoic acid diluted 1:500 in growth medium
(final retinoic acid concentration = 3.33 mM). One day later, media were fully exchanged for a
serum-free differentiation medium #2. This medium consisted of BDNF diluted 1:200 in
DMEM/F12 (supplemented only with the 0.5% antibiotic/antimycotic mixture; final BDNF
concentration 1.85 μM). One day later, cells underwent experimental manipulations and were
assayed after 20 h of incubation. Others find that these differentiation factors promote cell cycle
arrest and the expression of mature neuron markers (i.e. a shift from nestin+ to microtubule
associated protein 2+ expression and a polarized morphology; Constantinescu et al., 2007;
Encinas et al., 2000).
2.3 Treatment:
Cells were treated with vehicle or HIV Tat (100 nM diluted in dH2O; ImmunoDx,
Woburn, MA), G1 (1 or 10 nM), or G36 (1 or 10 nM). G1 and G36 were dissolved in DMSO and
diluted to concentration in media (diluted 1:10,000).
2.4 Measurement of overall ROS production
The indicator 5-(and-6)- chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, acetyl
ester (CM-H2DCFDA, Invitrogen, Carlsbad, CA), which is de-acetylated to dichlorofluorescein
(DCF) was used to measure the levels of ROS production. Following the manufacturer’s
protocol, cells were loaded with 10 µM CM-H2DCFDA in warm HBSS for 45 min and then
washed twice before treatments were applied. Subsequently, two concentration-response
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experimental designs were used. In one design, cells were treated with Tat (100 nM) and the
GPER1 agonist, G1, ranging in concentration from 0.01 nM to 10 nM. In another design, the
GPER1 antagonist, G36, ranging from 0.01 nM to 10 nM and Tat was held at 100 nM.
Fluorescence was measured (ex/em = 485/520 nm) using a CLARIOstar (BMG Labtech, Inc.,
Cary, NC) microplate reader. ROS levels (quantified by arbitrary fluorescent units) were
normalized to vehicle control cells and presented as the % change from control (n = 6-10
independent experiments).
2.5 Live/Dead Assay
After the treatment, a live/dead assay was conducted 20 h later to assess neuron
viability/necrosis. Prior work utilizing time-lapsed microscopy (0–60 h) identified the 20 h
time-point as the earliest time when pregnane steroid treated cells diverged from those that were
Tat-treated on the measure of viability (Paris et al., 2016). Until ready for imaging, cells were
incubated at 37 °C with 5% CO2 in the dark. 15 minutes prior to imaging, a working solution of
propidium iodide (ex/em: 535/617 nm) and Hoechst 33342 (ex/em: 360/460 nm) was prepared
by diluting stocks in Hank's Balanced Salt Solution (1:50 dilution) and then applied to the cells.
Plates were imaged using a Ti2-E motorized, inverted microscope (Nikon Instruments Inc.,
Melville, NY). Using ImageJ Fiji software (Schindelin et al., 2012), the number of dead cells and
total cells were quantified. The proportion of necrotic cells was calculated: [(propidium iodide +
cell # / total cell #) ∗ 100].
2.6 Statistical analyses
Cell viability was assessed via two-way analyses of variance (ANOVA) with Tat
condition (vehicle- or Tat-exposed) and GPER1 pharmacological treatment (vehicle, 1, or 10
nM G1 or G36) as factors. ROS was analyzed via repeated-measures ANOVA with Tat condition
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(vehicle- or Tat-exposed) as the between-subjects factor and GPER1 pharmacological treatment
(0-10 nM G1 or G36) as the within-subjects factor. To determine group differences main effects
were followed by Fisher’s Protected Least Significant Difference post-hoc tests (with all possible
pairwise comparisons made). Interactions were delineated via simple main effects and main
effect contrasts (corrected for family-wise error). For all the tests an alpha level of 0.05 was used
to determine significance.
3. RESULTS:
3.1 HIV Tat increased, and GPER1 agonism attenuated, ROS in SH-SY5Y cells
To ensure the quality of ROS assessment via DCF fluorescence, positive controls were
first assessed (Fig. 1). Compared to vehicle control, hydrogen peroxide (H2O2) significantly
increased DCF fluorescence whether applied 24 h or 1 h prior to assay [F(3,28) = 10.35, p <
0.0001 - 0.03] (Fig. 1). SH-SY5Y cells were treated with vehicle or Tat in combination with the
GPER1 agonist, G1 (0, 0.01, 0.1, 1, or 10 nM). Tat exposure significantly interacted with G1
concentration [F(4,56) = 2.73, p < 0.05] (Fig. 2A). Exposure to Tat significantly increased ROS
(indicated by an increase in the proportional DCF fluorescence) compared to control
vehicle-treated wells (p = 0.002). Any concentration of G1 significantly attenuated Tat-mediated
increases in ROS signal (p = 0.0001 - 0.04; Fig. 2A). Conversely, when cells were treated with
the GPER1 antagonist, G36, only Tat significantly influenced ROS. There was a main effect for
Tat exposure to significantly increase ROS compared to vehicle-treated control cells [F(1,72) =
23.05, p < 0.05] (Fig. 2B).
3.2 HIV Tat increased SH-SY5Y cell death, but not when GPER1 was agonized
SH-SY5Y cells were exposed to Tat protein and assessed for viability via live-dead assay
against G1 (1 or 10 nM; Fig. 3A). Tat and G1 exposure significantly interacted [F(2,54) = 3.50, p
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< 0.05] such that only Tat administration alone significantly increased cell death compared to
vehicle-treated controls (p = 0.03; Fig. 3A). G1-treated control groups had notably greater cell
death than did vehicle-treated controls, but these were not significantly different. When
SH-SY5Y cells were exposed to G36 (1 or 10 nM), only a main effect for Tat to significantly
increase cell death was observed [F(1,42) = 5.11, p < 0.05] (Fig. 3B). Seeding density (assessed
by counting the number of live and dead nuclei via Hoechst stain) did not significantly differ
across treatment groups in either experiment (170-227 cells/field in Experiment #1 and 141-193
cells/field in Experiment #2).
4. DISCUSSION:
The initial hypothesis that the GPER1 agonist, G1, would exert protective effects over
Tat-mediated cytotoxicity, whereas the GPER1 antagonist, G36, would not, were partially
upheld. Consistent with prior work, the addition of Tat increased cellular ROS (Fitting et al.,
2014; Smith et al., 2018) and promoted cell death in SH-SY5Y cells (Salahuddin et al., 2020;
Paris et al., 2020; Zhu et al., 2009). Activating GPER1 attenuated the Tat-mediated production of
ROS at any concentration assessed. Notably, the greatest concentration of G1 (i.e. 10 nM) also
reduced baseline ROS, irrespective of Tat treatment. These data support the notion that GPER1
activation may serve to modulate intracellular signaling via ROS. The activation of GPER1
promotes rapid mobilization of intracellular Ca2+ stores and thereby stimulates production of
ROS (Lei et al., 2017). Tat did increase cell death as expected, but results for G1 agonism to
protect SH-SY5Y cells were ambiguous. G1 did prevent Tat from significantly increasing cell
death, but may have also exerted some toxic effects on its own; more observations are needed to
disambiguate these results. Conversely, antagonizing GPER1 with G36, did not prevent
Tat-mediated ROS production. However, a notable reduction was observed at any concentration.
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While not significant, G36 did cause some reduction in ROS production on its own which may
have contributed to this effect. Consistent with this, G36 did not alter Tat’s capacity to promote
cell death. These findings extend what was previously known.
While on cART, women typically present with a higher CD4+ T-cell count in comparison
to men and CD4 count can be associated with mortality in HIV patients (Maskew et al., 2013).
HIV-infected women present with greater immune activation than men and typically progress
less quickly to NeuroHIV than men (Griesbeck et al., 2016). Some of the potential protective
effects observed in women may be conferred by actions of endogenous steroids. In particular,
pregnane steroids may ameliorate HIV protein-mediated neurotoxicity, partly via actions at
non-traditional receptor targets. In support, the progestogen, allopregnanolone (AlloP), is a
potent, positive allosteric modulator of GABA(A) receptors (Majewska et al., 1986; Paul and
Purdy, 1992) which is produced in response to immune challenges (Billiards et al., 2002; Ghezzi
et al., 2000). It is also an antagonist at L-type calcium channels (Earl and Tietz, 2011) and a
negative allosteric modulator of NMDA receptors when sulfated (Johansson and Le Grevès
2005; Maurice et al., 2006). AlloP may possess potential protective effects over HIV induced
neurological dysfunction (Paris et. al, 2020). In some studies, it was found that progesterone was
minimally protective (Kendall et al., 2005; Wallace et al., 2006); while, estrogen with its
antioxidant properties attenuated microglial activation in response to Tat or gp120 (Bruce-Keller
et al., 2001; Corasaniti et al., 2005; Zemlyak et al., 2005). Hence, the novel targets of estrogens
and progestogens should be investigated for their capacity to improve neurological dysfunction
(Paris et al., 2016). Studies using a transgenic mouse model, find an initial underlying difference
in male versus female vulnerability to Tat exposure; all the cases where severity differed between
sexes found, Tat-exposed male mice to have poorer outcomes, while Tat-exposed females were
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similar to controls. Males also showed an enhanced state of glial activation and synaptic damage,
similar to cognitive and motor impairments in HIV patients (Hahn et al., 2015). Estrogen is
generally considered neuroprotective and can attenuate or prevent Tat-induced neurotoxicity. The
mechanism(s) involved are not known but GPER1 is a novel component to investigate.
There are several mechanisms by which GPER1 may be beneficial for HIV-mediated
neurotoxicity. Although not clearly understood, GPER1 has been observed in the hypothalamus
(Xu et al., 2009), pituitary gland (Hazell et al., 2009), hippocampal formation, and amygdala
(Tian et al., 2013) in both male and female rodents. This may indicate that GPER1 plays a role in
the control of emotions and regulation of endocrine responses. Moreover, GPER1 also exhibits a
role in lexical cognitive function as it is expressed in the cholinergic neurons of the basal
forebrain. (Hammond and Gibbs, 2011). It has also been noted that GPER1 signals via G(s)
proteins, stimulating cAMP production, and triggering cleavage of membrane-tethered
heparin-bound epidermal growth factor (EGF). Hence, this results in transactivation of the EGF
receptor, intracellular Ca2+ mobilization and ERK1/2 activation (Olde Björn, and L M Fredrik
Leeb-Lundberg, 2009 ). In one study, G-1 increased the level of cAMP response element binding
(CREB) protein and binding of NF-κB to the promoter region for glutamate transporters in rat
primary astrocytes, thereby enhancing neuroprotection (Hadjimarkou, Maria M, and Nandini
Vasudevan, 2018). Another study suggests that GPER1 promotes neuroprotection in cultured
cortical neurons via its ability to signal death associated protein kinase 1 (DAPK1) and to
downregulate subtype 2B containing NMDA receptors. Thus, there may be different signalling
pathways downstream of GPER1 that exert neuroprotection (Vajaria, Ruby, and Nandini
Vasudevan, 2018). GPER1 may also interact with traditional estrogen receptors to exert
mitochondrial protection. When ROS is produced , intracellular Ca2+ increases, promoting
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reduced ATP, acetyl CoA, and an imbalance in the NADH/NAD + ratios, thus disrupting NFκB
signaling pathways. Signaling factors downstream of GPER1 can phosphorylate and activate
ERalpha receptors. Subsequently this leads to changes in the expression and activity of nuclear
respiratory factor 1 (NRF-1) and mitochondrial transcription factor A, ultimately stimulating
mitochondrial fusion which may help offset Tat’s mitotoxic capacity (Klinge et al., 2020).
The mechanisms by which GPER agonism influences ROS production are unclear. While
conducting the ROS assay, it was anticipated that exposure to Tat would increase the production
of ROS in the cells. When Tat is introduced into the cell, it activates Ca2+ excitatory ion channels,
promoting disruption of the membrane potential (Fitting et al., 2014). Mitochondria help
maintain homeostasis through storing the excess Ca2+ within their own membrane; this promotes
the production of ROS and the mitochondrial membrane potential can be compromised (Fitting
et al., 2014). The rapid production of ROS causes alterations in mitochondrial size and cellular
dysfunction. Hence, Tat promotes cell death via impairment of mitochondrial dynamics in
neurons. G1-decreases in ROS may occur following decreases in intracellular Ca2+. G1 also
appeared to decrease ROS on its own (irrespective of Tat) at the highest concentration suggesting
it has some inherent capacity to decrease ROS. Surprisingly, G36 did appear to reduce ROS
levels in response to Tat, although the attenuation was partial, not concentration-dependent, and
only occurred when Tat was present. This partial attenuation did not reach statistical significance.
Other GPER1 antagonists have been later found to have partial agonist activity (e.g. G15); albeit,
this has not yet been reported for G36.
Targeting non-traditional endocrine receptors may promote therapeutic advancement in
the field of neurological diseases including neuroHIV. Novel, steroid-based therapeutics have
been increasingly explored and found to reduce Tat mediated neuropathology. The
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didehydro-cortistatin A (dCA), a marine sponge glucocorticoid analogue, prevents Tat's capacity
to transactivate the HIV LTR and improves Tat-induced inflammation; it also attenuates Tat's
capacity to potentiate cocaine-mediated conditioned place preference (Mediouni et al., 2019,
2015; Mousseau et al., 2012). Also S-equol, an estrogen receptor β (ERβ)-acting isoflavone,
inhibits Tat-mediated synaptic loss in an ER-β-dependent manner with or without influence by
cocaine (Bertrand et al., 2015). Steroid mechanisms may also play a role in reducing interactions
with drugs of abuse including opioids. One of the findings show that oxycodone, a clinical
opioid, plays a role in down-regulating classic and novel estrogen receptor gene expression such
as ERα and GPER1 in human neuroblastoma cells. Other findings have presented ER
involvement in the desensitization of Mu-opioid receptor, partially explaining interactions
between these systems (Micevych et al., 2009). Thus, for the opioid-using population (licit and
illicit), adjunctive therapeutics that can maintain endogenous hormone milieu may be beneficial
for neuroHIV (Paris et al., 2020).
Due to the onset of SARS-CoV-2, the live/dead assay experiments associated with G1
were interrupted. The results presented contain preliminary data wherein there was high baseline
variance, particularly for the G1 live/dead assays. This may have been caused in part by the
large, non-optimal spread in seeding density that is noted for these assays. This thesis was also
intended to include a behavioral component assessing the cognitive effects of GPER1
agonists/antagonists on Tat expression in transgenic mice; however, these experiments were
interrupted by SARS-CoV-2 and are still ongoing in the lab.
In conclusion, exposure of SH-SY5Y neuroblastoma cells to HIV Tat resulted in
increased production of ROS and subsequent cell death. GPER1 agonism attenuated Tat induced
ROS production and attenuated cell death. The agonist G1 and antagonist G36 had some
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perplexing common effects to both reduce ROS. As all doses of G1 were effective in blocking
Tat-mediated ROS, future studies should focus at lower concentrations, and include a time
course study to assess how long the protection may last. The mechanisms involving potential
GPER1-mediated neuroprotection are not yet known. Further investigations regarding GPER1
and its mechanisms may reveal novel therapeutic targets for the treatment of neuroHIV and
related neurological disorders.
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Figure 1: Quality of ROS assessment via DCF fluorescence with H2O2 whether applied 24 h or 1
h prior to assay.
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Figure 2A: Percent ROS production in DCF with addition of Tat (100 nM) and varying
concentrations of G1.

Figure 2B: Percent ROS production in DCF with addition of Tat (100 nM) and varying
concentrations of G36.
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Figure 3A: Percent cell death of SH-SY5Y cells exposed to varying concentration of G1, with or
without exposure to Tat (100 nM).

Figure 3B: Percent cell death of SH-SY5Y cells exposed to varying concentration of G36, with
or without exposure to Tat (100 nM).
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